95 related articles for article (PubMed ID: 15241439)
1. Graft-versus-myeloma: are durable responses a clinical reality following donor lymphocyte infusion?
Peggs K; Mackinnon S
Leukemia; 2004 Sep; 18(9):1541-2; author reply 1542-3. PubMed ID: 15241439
[No Abstract] [Full Text] [Related]
2. Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions.
Hoevenaren IA; van Vulpen LF; Levenga H; Minnema MC; Raymakers R
Bone Marrow Transplant; 2011 Feb; 46(2):319-21. PubMed ID: 20305701
[No Abstract] [Full Text] [Related]
3. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.
Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J
Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296
[TBL] [Abstract][Full Text] [Related]
4. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.
Maury S; Lemoine FM; Hicheri Y; Rosenzwajg M; Badoual C; Cheraï M; Beaumont JL; Azar N; Dhedin N; Sirvent A; Buzyn A; Rubio MT; Vigouroux S; Montagne O; Bories D; Roudot-Thoraval F; Vernant JP; Cordonnier C; Klatzmann D; Cohen JL
Sci Transl Med; 2010 Jul; 2(41):41ra52. PubMed ID: 20650872
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma.
Ayuk F; Shimoni A; Nagler A; Schwerdtfeger R; Kiehl M; Sayer HG; Zabelina T; Zander AR; Kröger N
Leukemia; 2004 Mar; 18(3):659-62. PubMed ID: 14671630
[No Abstract] [Full Text] [Related]
6. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
[TBL] [Abstract][Full Text] [Related]
7. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy does not nullify the ability of donor lymphocyte infusions to mediate graft-versus-host reactions.
Fuchs EJ; Seber A; Altomonte V; Braine HG; Humphrey RL; Jones RJ; Noga SJ; Schepers K; Wright SK; Vogelsang GB
Bone Marrow Transplant; 1998 Aug; 22(3):303-5. PubMed ID: 9720749
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect.
Khaled Y; Mellacheruvu S; Reddy P; Peres E; Mineishi S
Bone Marrow Transplant; 2009 Sep; 44(5):325-6. PubMed ID: 19204708
[No Abstract] [Full Text] [Related]
10. Multiple myeloma: role of allogeneic transplantation.
Pandit S; Vesole DH
Oncology (Williston Park); 2002 Sep; 16(9):1268-74; discussion 1274-6. PubMed ID: 12380950
[TBL] [Abstract][Full Text] [Related]
11. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
Zeis M; Steinmann J; Petrela E; Hartung G; Schmitz N; Uharek L
Bone Marrow Transplant; 2001 Feb; 27(3):279-85. PubMed ID: 11277175
[TBL] [Abstract][Full Text] [Related]
12. Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma.
Chiriva-Internati M; Wang Z; Salati E; Wroblewski D; Lim SH
Scand J Immunol; 2002 Oct; 56(4):429-33. PubMed ID: 12234264
[TBL] [Abstract][Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
14. Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation.
Libura J; Hoffmann T; Passweg J; Gregor M; Favre G; Tichelli A; Gratwohl A
Bone Marrow Transplant; 1999 Oct; 24(8):925-7. PubMed ID: 10516707
[TBL] [Abstract][Full Text] [Related]
15. [Allogeneic bone marrow transplantation for refractory multiple myeloma: presence of a graft-versus-myeloma effect].
Nawa Y; Noguchi T; Kojima K; Hara M
Rinsho Ketsueki; 2001 Jun; 42(6):481-7. PubMed ID: 11505527
[TBL] [Abstract][Full Text] [Related]
16. Induction of multiple myeloma-reactive T cells during post-transplantation immunotherapy with donor lymphocytes and recipient DCs.
Broen K; Greupink-Draaisma A; Fredrix H; Schaap N; Dolstra H
Bone Marrow Transplant; 2012 Sep; 47(9):1229-34. PubMed ID: 22246088
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect.
Zeiser R; Finke J
Eur J Cancer; 2006 Jul; 42(11):1601-11. PubMed ID: 16759847
[TBL] [Abstract][Full Text] [Related]
18. Pro: allogeneic transplantation in multiple myeloma.
Gahrton G
Clin Adv Hematol Oncol; 2006 May; 4(5):388-91. PubMed ID: 16728947
[No Abstract] [Full Text] [Related]
19. Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect.
Cervantes F; Rovira M; Urbano-Ispizua A; Rozman M; Carreras E; Montserrat E
Bone Marrow Transplant; 2000 Sep; 26(6):697-9. PubMed ID: 11035377
[TBL] [Abstract][Full Text] [Related]
20. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
